Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant

Description

Can the investigators create an effective way to improve adherence to immunosuppressant medication and reduce rejection, graft loss, and death in adolescents and young adults who have undergone kidney or liver transplantation? The investigators' mobile technology intervention uses real-time electronic pillbox-assessed dose timing and text message prompts to address antirejection medication nonadherence when nonadherence is detected.

Conditions

Transplant;Failure,Kidney, Transplant; Failure, Liver, Adherence, Medication, Adherence, Patient, Adherence, Treatment

Study Overview

Study Details

Study overview

Can the investigators create an effective way to improve adherence to immunosuppressant medication and reduce rejection, graft loss, and death in adolescents and young adults who have undergone kidney or liver transplantation? The investigators' mobile technology intervention uses real-time electronic pillbox-assessed dose timing and text message prompts to address antirejection medication nonadherence when nonadherence is detected.

Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients: A Micro-Randomized Trial

Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant

Condition
Transplant;Failure,Kidney
Intervention / Treatment

-

Contacts and Locations

Baltimore

Johns Hopkins, Baltimore, Maryland, United States, 21287

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adolescents and young adults (13-25 years old) who underwent kidney or liver transplantation at least 6 months prior to enrollment
  • * Currently prescribed tacrolimus or sirolimus.
  • * Currently receiving dialysis
  • * Hospitalized for duration of study
  • * Significant developmental or cognitive delay
  • * No access to a mobile device that supports text messaging
  • * Decline to use electronic pill box to monitor daily medication adherence
  • * Non-English speaking
  • * If a participant meets inclusion criteria, enrolls in the study, and experiences graft failure potentially leading to dialysis in the case of kidney transplant recipients, the participant will be given the option to continue in the study if they remain on tacrolimus or sirolimus.

Ages Eligible for Study

13 Years to 25 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Johns Hopkins University,

Cyd Eaton, PhD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

2026-06